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Virus-like particle vaccines
Against BK and JC polyomaviruses
Diana V. Pastrana
Buck Lab
National Cancer Institute, NIH, USA
Human Polyomaviruses
BK polyomavirus (BKV)
• Poly + Oma = “Many Tumors”
• 11 human polyomavirus types





• Poly + Oma = “Many Tumors”
• 11 human polyomavirus types
• Lifelong infection is common and generally 
asymptomatic, but…
• BKV present in transplanted organs causes 
kidney and bladder damage
3• JCV causes brain disease (PML) in immunosuppressed patients
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• Each day, four US kidney 
transplant recipients lose 
their graft due to BKV












Neutralizing Antibodies Are Protective
8
• “A neutralizing antibody titer against the donor’s strain <10,000 
before transplant significantly associate with BKV replication 
after transplant”
Case Study – BKV nephropathy
NIH Ref. No.: E-168-2011 9
Kidney donor was co-infected 
with BKV-I and BKV-IV
Peretti et al, 2018 Cell Host & Microbe
Case Study – BKV nephropathy
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Case Study – BKV nephropathy
NIH Ref. No.: E-168-2011 11
Papillomavirus Polyomavirus
12
Polyomaviruses Also Form VLPs
Lessons of the HPV Vaccine
Papillomavirus (HPV16)
• Recombinant HPV virus-like particles (VLPs) are extraordinarily 
effective for eliciting durable high-titer neutralizing antibody 






































Monkeys immunized with BKV-IV VLPs
• Polyomavirus VLPs 
induce protective 
neutralizing antibody 
responses in monkeys 
after a single dose
protective











The Path to Market (Post-Transplant Kidney Damage)
16
2019





• GMP development 
($5m through CRO)
GMP VLPs
• NCI assistance 
(application in process)
The Path to Market (Post-Transplant Kidney Damage)
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GMP VLPs Phase 1/2
2019-2020
• Trial: vaccinate 96 patients 
on kidney transplant wait-list
• Standard monitoring for 
viremia, 24 weeks
The Path to Market (Post-Transplant Kidney Damage)
19
GMP VLPs Phase 1/2 Market
2020-2021
• The polyomavirus VLP vaccine is 
eligible for the FDA’s Expedited 
Programs for Serious Conditions. 
This allows post-marketing 
confirmation of efficacy
The Path to Market (Post-Transplant Nephropathy)
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Brain Disease (PML) in 
immunosuppression 
Brain Disease (PML)
• The PROBLEM: 
• Polyomaviruses (JCV) causes a brain disease called 
progressive multifocal leukoencephalopathy (PML). AIDS 
patients and individuals taking many types of 






Rank Tradename Generic 2016 sales ($b)
FDA-reported PML 
cases
1 Humira adalimumab 16 83
2 Sovaldi/Harvoni sofosbuvir 9 1
3 Enbrel etanercept 9 73
4 Rituxan rituximab 9 413
5 Remicade infliximab 8 113
PML black box warning
23
Other Drugs with Black Box PML Warning
ehealthme.com
genengnews.com
Tradename Generic 2016 sales ($b)
FDA-reported PML 
cases
Tysabri natalizumab 2 4332
Raptiva efalizumab 0 27
Myfortic mycophenolic acid 0.09 13
Adcetris brentuximab vedotin 0.07 25
Entyvio vedolizumab 1.4 0
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Other Drugs with Black Box PML Warning
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Tradename Generic 2016 sales ($b)
FDA-reported PML 
cases
Tysabri natalizumab 2 4332
Raptiva efalizumab 0 27
Myfortic mycophenolic acid 0.09 13
Adcetris brentuximab vedotin 0.07 25
Entyvio vedolizumab 1.4 0
About a third of MS patients who 
want Tysabri are turned away due 
to PML risk stratification
25
Other Drugs with Black Box PML Warning
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Tradename Generic 2016 sales ($b)
FDA-reported PML 
cases
Tysabri natalizumab 2 4332
Raptiva efalizumab 0 27
Myfortic mycophenolic acid 0.09 13
Adcetris brentuximab vedotin 0.07 25
Entyvio vedolizumab 1.4 0
License revoked
PML Side-Effects Cast a Long Shadow
26
Entyvio TV ad: “While 
not reported with 
Entyvio, PML - a rare 




• Co-therapy for patients taking 
Tysabri, Rituxan, Entyvio, and 
many other high-grossing 
immunosuppressive therapies. 
20-50 million Americans have 
autoimmune disorders 
treatable with these therapies
• People living with HIV
http://bioethicsbulletin.org/archive/how-many-americans-are-immunocompromised
A Lack of Neutralizing Antibodies
NIH Ref. No.: E-168-2011
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Some healthy adults who robustly neutralize 
w.t. JCV fail to neutralize some PML mutant 
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PML Patient 5040 (Survivor) 
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PML Patient 5029 (Progressor) 
PML Diagnosis 
Patient gained the ability to neutralize
†




• Multivalent BKV-Ib, II, IV, 
JCV VLP vaccine: good 
immunogenicity in monkeys
The Path to Market (PML)
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GMP VLPs Phase 1/2
2019-2020
• Trial: vaccinate 24 PML patients. 
Monitor PML progression rate 
relative to 12 control PML patients
The Path to Market (PML)
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GMP VLPs Phase 1/2
2020-2021
• This intervention is eligible for FDA’s 
Expedited Programs for Serious 
Conditions. This allows post-




• Indication 1: prevention of polyomavirus nephropathy in 
transplant patients. Predicted US market $600 million/year
33
Conclusions
• Indication 1: prevention of polyomavirus nephropathy in 
transplant patients. Predicted US market $600 million/year
• Indication 2: prevention of bladder disease after bone marrow 
transplant. Predicted US market $400 million/year plus an 
uncertain fraction of 250,000 patients diagnosed with 
conditions that may require transplant
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Conclusions
• Indication 1: prevention of polyomavirus nephropathy in 
transplant patients. Predicted US market $600 million/year
• Indication 2: prevention of bladder disease after bone marrow 
transplant. Predicted US market $400 million/year plus an 
uncertain fraction of 250,000 patients diagnosed with 
conditions that may require transplant
• Indication 3: prevention of PML side effects in individuals 
taking top-selling immunosuppressive therapies. $Billions
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Conclusions (continued)
• All indications are serious conditions with no currently 
available treatment. New FDA programs allow accelerated 
approval with post-marketing efficacy
• NCI has been issued patents covering these technologies. 
Exclusive licensing remains possible
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Patent Status
NOTE: polyvalent BKV/JCV vaccine can protect against both kidney disease in 
transplant patients and PML in immuno-modulatory patients. 
• Allowed Claims
• US (14/233,582) – Method of eliciting an immune response to BKV/JCV 
by administering to a patient an effective amount of a trivalent BKV/JCV 
vaccine (BKV-Ib2, BKV-IV and JC antigens) – NIH Ref. No. E-168-2011
• JAPAN (2014-521716) – Vaccine compositions directed to a trivalent 
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For Licensing: 
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National Cancer Institute 
Phone: 240-276-6910
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